Sensei Biotherapeutics (NASDAQ:FTH) Coverage Initiated by Analysts at JonesTrading

Stock analysts at JonesTrading started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $55.00 price target on the stock. JonesTrading’s price objective would suggest a potential upside of 131.34% from the company’s current price.

Several other equities research analysts have also recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a report on Thursday, May 28th. HC Wainwright began coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price for the company. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Stock Down 13.0%

FTH traded down $3.56 on Tuesday, hitting $23.77. 344,921 shares of the company’s stock were exchanged, compared to its average volume of 200,596. Sensei Biotherapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $37.90. The stock has a market cap of $31.91 million, a PE ratio of -0.17 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $4.42. As a group, research analysts anticipate that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insider Activity

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider owned 130,142 shares of the company’s stock, valued at $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently made changes to their positions in FTH. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the 1st quarter worth approximately $22,758,000. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the last quarter. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.